

New Process for Acquiring Botox

CVS Specialty® pharmacy (Caremark) notified Florida Blue that effective Jan. 1, 2022, they will no longer stock or dispense Botox. Providers wishing to administer Botox will no longer be able to access it through “Drug Replacement” from CVS Specialty. Providers will need to maintain their own supply, request authorization through the appropriate channel (listed below) and submit claims to Florida Blue for reimbursement.

What You Need to Know

- CVS Specialty will no longer accept new prior authorization requests for Botox effective Dec. 18, 2021.
- Additionally, CVS Specialty will stop stocking and dispensing Botox for all patients effective Jan. 1, 2022.
- Alternatives that will still be supplied by CVS Specialty Pharmacy include Xeomin, Myobloc and Dysport.

Florida Blue Commercial and Truli for Health

Effective **Dec. 18, 2021**, Providers should submit all **new** Commercial and Truli for Health Prior Authorizations requests for Botulinum Toxin drugs through MagellanRx, as they do today when purchasing drugs and billing Florida Blue directly for reimbursement (“Buy and Bill”).

- Prior authorization requests should be submitted to MagellanRx.
 - <http://ih.magellanrx.com/>
 - **1-800-424-4947**
- Provider will need to acquire the drug through their current suppliers or may arrange supply by contacting Allergan, [the manufacturer of Botox.](#)
- There will be **no change** to [Medical Coverage Guidelines](#) for Botox.

Medicare

- Medicare “Buy and Bill” prior authorization requests should be sent directly to Florida Blue by using the self-service tools at [Availity](#), or by contacting Florida Blue directly at **1-800-727-2227**, then select “Authorization Referral.”

Medicare Part D Network Pharmacy only

- Providers requesting prior authorization for Medicare members for Botox dispensed by a Medicare Part D network pharmacy will continue to use [Prime Therapeutics](#) for Part D authorizations.
 - **1-800-926-6565**